<DOC>
	<DOCNO>NCT02146937</DOCNO>
	<brief_summary>This open label , single site , single arm Phase II study evaluate combination bicalutamide plus finasteride men MRI detectable significant prostate nodule follow active surveillance .</brief_summary>
	<brief_title>A Phase 2 Study Bicalutamide Plus Finasteride Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance</brief_title>
	<detailed_description>This research do determine negative re-biopsy rate determine MRI/TRUS fusion guide biopsy target dominant nodule site define pre-treatment MRI follow three month ( 90 day ) combination bicalutamide plus finasteride .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Willing able provide write informed consent . 2 . Age ≥ 18 year 3 . Eastern cooperative group ( ECOG ) performance status ≤2 4 . Documented histologically confirm adenocarcinoma prostate ( minimum 12 core prostate biopsy complete within 90 day screen ) 5 . Very lowrisk prostate cancer define : Gleason score ≤ 6 PSA density ≤ 0.15 ng/mL/mL PSA &lt; 10 ng/mL Clinical tumor stage T1 ( cT1 ) ( i.e. , palpable nodule digital rectal exam ) ≤2 prostate core positive prostatic adenocarcinoma ≤50 % give core involved prostatic adenocarcinoma 6 . Willing qualify active surveillance Johns Hopkins 7 . Presence least one MRI significant visible prostate tumor ( i.e. , ≥5 mm least one dimension ) biopsy prove prostatic adenocarcinoma Note : MRI may occur pre postprostate biopsy . If do postbiopsy , MRI must occur &lt; 8 week postprostate biopsy . 8 . Serum testosterone ≥150 ng/dL 9 . Able swallow study drug whole tablet 1 . Prior local therapy treat prostate cancer ( e.g. , radical prostatectomy , radiation therapy , brachytherapy ) 2 . Prior use bicalutamide 3 . Prior use finasteride within past year 4 . Prior ongoing systemic therapy prostate cancer include , limited : Hormonal therapy ( e.g. , leuprolide , goserelin , triptorelin ) CYP17 inhibitor ( e.g. , abiraterone , ketoconazole ) Antiandrogens ( e.g. , bicalutamide , flutamide , nilutamide ) Second generation antiandrogens ( e.g. , enzalutamide , ARN509 ) Immunotherapy ( e.g. , sipuleucelT , ipilimumab ) Chemotherapy ( e.g. , docetaxel , cabazitaxel ) 5 . Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study . 6 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule . 7 . Abnormal bone marrow function [ absolute neutrophil count ( ANC ) &lt; 1500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin &lt; 9 g/dL ] 8 . Abnormal liver function ( bilirubin , AST , ALT ≥ 3 x upper limit normal ) 9 . Abnormal kidney function ( serum creatinine ≥ 2 x upper limit normal ) 10 . Abnormal cardiac function manifest NYHA ( New York Heart Association ) class III IV heart failure history prior myocardial infarction ( MI ) within last five year prior enrollment study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>active surveillance</keyword>
	<keyword>MRI/transrectal ultrasound fusion guide biopsy</keyword>
	<keyword>biopsy</keyword>
</DOC>